0 268

Cited 11 times in

A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma

DC Field Value Language
dc.contributor.author박준용-
dc.contributor.author한광협-
dc.date.accessioned2020-07-27T16:40:55Z-
dc.date.available2020-07-27T16:40:55Z-
dc.date.issued2015-04-
dc.identifier.issn0344-5704-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/178449-
dc.description.abstractPurpose: This multicenter, randomized, open-labeled, clinical trial evaluated the efficacy and safety of cisplatin/5-fluorouracil (5-FU) hepatic arterial infusion chemotherapy (CF-HAIC) versus adriamycin adding to CF-HAIC (ACF-HAIC) in advanced HCC patients. Methods: Fifty-six patients with advanced HCC were randomized to two treatment groups: (1) CF-HAIC group [n = 29, 5-FU, 500 mg/m(2) on days 1-3, and cisplatin, 60 mg/m(2) on day 2] and (2) ACF-HAIC group [n = 27, adriamycin, 50 mg/m(2) on day 1, 5-FU, 500 mg/m(2) on days 1-3, and cisplatin, 60 mg/m(2) on day 2] every 4 weeks via an implantable port system. Primary efficacy endpoint was overall survival (OS). Treatment response and time to progression were secondary endpoints. Results: Treatment response rates did not differ significantly between the two treatment groups. Time to progression (5.4 vs. 5.8 months, P = 0.863) and OS (11.1 vs. 8.8 months, P = 0.448) were not significantly different. When the factors affecting patient OS were analyzed, disease control rate [P < 0.001, HR 6.437 (95% CI 2.580-16.064)] was independently associated with OS. Age (≥60 years) and serum AFP level (≥200 ng/dL) also were significant factors for OS [P = 0.007, HR 4.945 (95% CI 1.543-15.850), P = 0.048, HR 2.677 (95% CI 1.010-7.095), respectively]. Grade 4 treatment-related toxicity and mortality was not observed in both groups. Conclusions: Although both HAIC regimens are safe and effective in patients with advanced HCC, HAIC adding adriamycin did not show delayed tumor progression and survival benefit compared to CF-HAIC in advanced HCC.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer Verlag-
dc.relation.isPartOfCANCER CHEMOTHERAPY AND PHARMACOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / administration & dosage-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols / therapeutic use*-
dc.subject.MESHCarcinoma, Hepatocellular / drug therapy*-
dc.subject.MESHCarcinoma, Hepatocellular / pathology-
dc.subject.MESHCisplatin / administration & dosage-
dc.subject.MESHCisplatin / adverse effects-
dc.subject.MESHCisplatin / therapeutic use-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHDoxorubicin / administration & dosage-
dc.subject.MESHDoxorubicin / adverse effects-
dc.subject.MESHDoxorubicin / therapeutic use-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil / administration & dosage-
dc.subject.MESHFluorouracil / adverse effects-
dc.subject.MESHFluorouracil / therapeutic use-
dc.subject.MESHHepatic Artery-
dc.subject.MESHHumans-
dc.subject.MESHInfusions, Intra-Arterial-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHLiver Neoplasms / drug therapy*-
dc.subject.MESHLiver Neoplasms / pathology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHProspective Studies-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHYoung Adult-
dc.titleA randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorMyeong Jun Song-
dc.contributor.googleauthorSi Hyun Bae-
dc.contributor.googleauthorHo Jong Chun-
dc.contributor.googleauthorJong Young Choi-
dc.contributor.googleauthorSeung Kew Yoon-
dc.contributor.googleauthorJun Young Park-
dc.contributor.googleauthorKwang Hyub Han-
dc.contributor.googleauthorYoung Seok Kim-
dc.contributor.googleauthorHyung Joon Yim-
dc.contributor.googleauthorSoon Ho Um-
dc.contributor.googleauthorWoo Jin Chung-
dc.contributor.googleauthorJae Seok Hwang-
dc.contributor.googleauthorSung-Bum Cho-
dc.contributor.googleauthorJong Ryul Eun-
dc.identifier.doi10.1007/s00280-015-2692-0-
dc.contributor.localIdA01675-
dc.contributor.localIdA04268-
dc.relation.journalcodeJ00437-
dc.identifier.eissn1432-0843-
dc.identifier.pmid25663125-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs00280-015-2692-0-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor한광협-
dc.citation.volume75-
dc.citation.number4-
dc.citation.startPage739-
dc.citation.endPage746-
dc.identifier.bibliographicCitationCANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.75(4) : 739-746, 2015-04-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.